Figure 5From: Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesIncidence of grade ≥ 3 AEs by treatment cycle. Cycles in which no grade ≥ 3 AEs were reported are not included.Back to article page